Retatrutide
Retatrutide is a synthetic tri-agonist peptide engineered to interact with GLP-1, GIP, and glucagon receptor signaling pathways. Through this tri-agonist mechanism, it is utilized in research settings to study metabolic signaling processes, receptor signaling pathways, and peptide-mediated cellular communication. Supplied by Peptico for research-use only.
All Orders Ship within
24 Business Hours
Free Shipment Protection
Priority Shipment Options Available at Checkout
- For maximum potency, lyophilized materials may generally be stored between 2°C and 8°C (36°F to 46°F) for up to 4 weeks when maintained in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
- For maximum potency and long-term preservation, lyophilized materials may generally be stored between -20°C and -80°C (-4°F to -112°F) for up to 1 year when preserved in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
Important Note:
Storage guidelines apply only to lyophilized material in its original, sealed, and untampered vial.
COA History
All shipped products include a unique batch number printed on the vial label. This batch number corresponds to a third-party Certificate of Analysis tested by an ISO/IEC 17025 accredited laboratory.
The COA attached at the top of this page, along with the COA marked “Current” below, represents the active production batch currently being shipped. This same batch number will appear on the label of your vial.
For previous purchases, please refer to COAs marked “Historical” and match the batch number on your vial to the batch number listed on the corresponding COA.
For a complete record of testing documentation across all products and batches, please visit our COA Vault, which includes both current and historical COAs.
Molecular Profile
What is Retatrutide?
Research
Sources & References
API results related to Retatrutide.
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
Drug and alcohol review
Piatkowski T, Craven A, Cornell S et al. • 2026
Publication date: 2026 Sep
View sourceRetatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.
BMJ (Clinical research ed.)
Brown C • 2026
Publication date: 2026 Aug 7
View sourceIntegrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
Clinics in dermatology
Narla S, Narla RR • 2026
Publication date: 2026 Aug 6
View sourceThe role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
Pharmacological research
Roskoski R Jr • 2026
Publication date: 2026 Aug 5
View sourceRetatrutide effects on diabetic rats' cognition.
Lab animal
Ferreira J • 2026
Publication date: 2026 Aug
View sourceBeyond weight loss: multisystem benefits of obesity medications.
The lancet. Diabetes & endocrinology
Savas M, Kuckuck S, Boon MR et al. • 2026
Publication date: 2026 Aug
View source⚠️ IMPORTANT RESEARCH NOTICE
This product is NOT for human consumption.
Supplied strictly for laboratory and analytical research use only, it is not intended to diagnose, treat, cure, or prevent any disease, and must not be used for clinical, veterinary, or therapeutic applications.
All information provided, including referenced research and data, is for educational and scientific context only and should NOT be interpreted as medical guidance.
By purchasing, you confirm that you are a qualified individual or entity operating in accordance with applicable local, state, and federal regulations. All responsibility for handling, use, and compliance rests solely with the purchaser.








